Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Mar;50(3):425-7.
doi: 10.1136/gut.50.3.425.

Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

A K Burroughs  1 , R Groszmann, J Bosch, N Grace, G Garcia-Tsao, D Patch, J C Garcia-Pagan, L Dagher
Affiliations
Review

Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

A K Burroughs et al. Gut. 2002 Mar.

Abstract

Chronic hepatitis C is a major healthcare problem. The response to antiviral therapy for patients with chronic hepatitis C has previously been defined biochemically and by PCR. However, changes in the hepatic venous pressure gradient (HVPG) may be considered as an adjunctive end point for the therapeutic evaluation of antiviral therapy in chronic hepatitis C. It is a validated technique which is safe, well tolerated, well established, and reproducible. Serial HVPG measurements may be the best way to evaluate response to therapy in chronic hepatitis C.

PubMed Disclaimer

References

    1. Cohen J. The scientific challenge of hepatitis C. Science 1999;285:26–30. - PubMed
    1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(suppl 1):15–20S. - PubMed
    1. Pagliaro L, Peri V, Linea C, et al. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999;31:28–44. - PubMed
    1. Recomendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No RR-19):1–17. - PubMed
    1. Consensus Statement. EASL International Consensus Conference on Hepatitis C. Paris, 26–28 February 1999. J Hepatol 1999;30:956–61. - PubMed

MeSH terms

Substances